Opinion

Video

Novel Treatment Options for Bronchiectasis

Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.

Clinical Brief: Emerging Therapies for Bronchiectasis

Main Discussion Topics

  • DPP1 inhibitors target neutrophil inflammation in bronchiectasis.
  • Eosinophilic bronchiectasis (approximately 30% of cases) benefits from targeted therapies.
  • Approaches to treatment vary based on inflammatory phenotype.

Key Points for Physicians

  • DPP1 inhibitors:
    • Target abnormal neutrophil function and reduce neutrophil serine proteases
    • May prevent formation of neutrophil extracellular traps
  • Aim to reduce exacerbations and disease progression
  • For eosinophilic bronchiectasis (30% of cases):
    • Inhaled corticosteroids are beneficial
    • Anti-IL5 therapies show promise
    • Biologic therapies are being investigated
  • Discourage inhaled corticosteroids in neutrophilic bronchiectasis (70% of cases) due to potential infection risk.

Notable Insights

Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.

Clinical Significance

Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Gordon Crofoot, MD, PA
Dr Brian Slomovitz
4 experts are featured in this series.
2 experts in this video
2 experts in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo